Clinical Trial Detail

NCT ID NCT02052648
Title Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors NewLink Genetics Corporation
Indications

brain glioblastoma multiforme

malignant glioma

gliosarcoma

Therapies

Temozolomide

Indoximod

Age Groups: adult

No variant requirements are available.